Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and upcoming catalysts. We continue to see an interesting neurology platform case with an eventful future ahead. We believe that the current valuation of the company is undemanding and presents a favorable opportunity to enter at these levels.